BTIG analyst Mark Massaro raised the price target on Sophia Genetics SA (NASDAQ: SOPH) to $8.00 (from $7.00) while maintaining a Buy rating.

The analyst comments "What is unique about Sophia? SOPH is capturing real-time, multi-modal patient data, from all over the world, and is building an "intelligence layer" that can follow patients over time longitudinally, and at a lower price point than competing options. SOPH noted that diagnostics is a means to an end, and what it is really after is the longitudinal patient data, a strategy that is similar to that of Tempus (TEM, Buy, $90 PT), in our view. In prior years we think SOPH has received "negative credit" from investors for being global (started in Europe, has had some adverse FX impacts, lumpiness in regions like Latin America and others, liquid biopsy in the EU is ~six years behind the U.S.). However, we think it will become more evident to U.S. investors, and to numbers, that the company's global sales (in 75 countries) is a competitive advantage relative to U.S.-focused companies when it comes to its global patient longitudinal database and its resurgent biopharma business."